Article
Update on the Science of Myelodysplastic Syndromes
Scientific research is only just beginning to shed light on the pathobiology underlying the various subtypes of myelodysplastic syndromes (MDS), a heterogeneous group of clonal stem cell disorders characterized by cytopenias that can progress to acute myeloid leukemia. Increased understanding of the disease and prognostic implications of specific clinical features has aided in the development of prescribing guidelines and new treatments for MDS. Because oncology nurses have frequent interactions with patients during diagnostic and therapeutic evaluations, an understanding of the science behind disease classification, prognostic scoring, and the goals of treatment for low- and high-risk disease is important to answer questions regarding diagnostic results, treatment outcomes, and adverse event monitoring.
Jump to a section
References
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H. R., & Sultan, C. (1982). Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189-199.
Bevans, M. F., & Shalabi, R. A. (2004). Management of patients receiving antithymocyte globulin for aplastic anemia and myelodysplastic syndrome. Clinical Journal of Oncology Nursing, 8, 377-382. doi:10.1188/04.CJON.377-382
Blum, W. (2010). How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 314-321. doi:10.1182/asheducation-2010.1.314
Boehrer, S., Adès, L., Braun, T., Galluzzi, L., Grosjean, J., Fabre, C., … Kroemer, G. (2008). Erlotinib exhibits antineoplastic off-target effects in AML and MDS: A preclinical study. Blood, 111, 2170-2180. doi:10.1182/blood-2007-07-100362
Center for International Blood and Marrow Transplant Research. (2011). Report on state of the art in blood and marrow transplantation. Retrieved from http://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx
ClinicalTrials.gov. (2009). A phase 2 trial of RAD001 in low and intermediate-1 risk myelodysplastic syndromes. Retrieved from http://www.clinicaltrials.gov/ct2/show/NCT00809185
ClinicalTrials.gov. (2011). A study of ARRY-614 in patients with low or intermediate-1 risk myelodysplastic syndrome. Retrieved from http://www.clinicaltrials.gov/ct2/show/NCT00916227
Cutler, C. (2010). Patient selection for transplantation in the myelodysplastic syndromes. Hematology/Oncology Clinics of North America, 24, 469-476. doi:10.1016/j.hoc.2010.02.006
Cutler, C. S., Lee, S. J., Greenberg, P., Deeg, H. J., Perez, W. S., Anasetti, C., … Horowitz, M. M. (2004). A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood, 104, 579-585. doi:10.1182/blood-2004-01-0338
De Swart, L., Smith, A., Fenaux, P., Symeonidis, A., Hellstrom-Lindberg, E., Sanz, G., … Beyne-Rauzy, O. (2011). Management of 1,000 patients with low- and intermediate-1 risk myelodysplastic syndromes in the European LeukemiaNet MDS registry. Leukemia Research, 35(Suppl. 1), S3.
Díez Campelo, M., Córdoba, I., Gómez-García de Soria, S., Martirio, R., Sanz, G., Insunza, A., … del Cañizo, M. C. (2011). Allogeneic stem cell transplant for myelodysplastic syndromes: Results of 291 patients from Spanish MDS registry [Abstract 328]. Leukemia Research, 35(Suppl. 1), S131-S132.
Epling-Burnette, P., List, A. F., & Komrokji, R. S. (2011). Guidelines for immunosuppression in MDS [Abstract 10]. Leukemia Research, 35(Suppl. 1), S4.
Esteller, M. (2008). Epigenetics in cancer. New England Journal of Medicine, 358, 1148-1159. doi:10.1056/NEJMra072067
European Medicines Agency. (2012). Home page. Retrieved from http://www.ema.europe.eu
Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., … MDS-004 Lenalidomide del5q Study Group. (2011). A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood, 118, 3765-3776. doi:10.1182/blood-2011-01-330126
Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G. J., Mittelman, M., … Hellstrom-Lindberg, E. (2009). RBC transfusion independence and safety profile of lenalidomide 5 or 10 mg in patients with low- or int-1 risk MDS with del5q: Results from a randomized phase II trial (MDS-004) [Abstract 944]. Retrieved from http://ash.confex.com/ash/2009/webprogram/Paper21430.html
Fenaux, P., Kantarjian, H., Lyons, R. M., Larson, R. A., Sekeres, M. A., Becker, P. S., … Yang, A. S. (2011). Update of open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with MDS [Abstract 215]. Leukemia Research, 35(Suppl. 1), S84.
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., … International Vidaza High-Risk MDS Survival Study Group. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncology, 10, 223-232. doi:10.1016/S1470-2045(09)70003-8
Figueroa, M. E., Skrabanek, L., Li, Y., Jiemjit, A., Fandy, T. E., Paietta, E., … Melnick, A. (2009). MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood, 114, 3448-3458. doi:10.1182/blood-2009-01-200519
Flinn, I. W., Lang, E., Raefsky, E., Boccia, R., Macias-Perez, I. M., Burris, H. A. I., & Hainsworth, J. D. (2010). Preliminary results of a phase 2 trial of panobinostat (LBH589) in refractory myelodysplastic syndromes (MDS) patients [Abstract 4015]. Retrieved from http://ash.confex.com/ash/2010/webprogram/Paper29441.html
Garcia-Manero, G. (2010). Prognosis of myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 330-337. doi:10.1182/asheducation-2010.1.330
Garcia-Manero, G. (2011). Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 86, 490-498. doi:10.1002/ajh.22047
Garcia-Manero, G., & Fenaux, P. (2011). Hypomethylating agents and other novel strategies in myelodysplastic syndromes. Journal of Clinical Oncology, 29, 516-523. doi:10.1200/JCO.2010.31.0854
Garcia-Manero, G., Gore, S. D., Cogle, C., Ward, R., Shi, T., MacBeth, K. J., … Skikne, B. (2011). Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Journal of Clinical Oncology, 29, 2521-2527. doi:10.1200/JCO.2010.34.4226
Giagounidis, A., Ghulam, J., Kantarjian, H. M., Fenaux, P., Sekeres, M. A., Szer, J., … Jun, S. (2011). Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (Int-1) risk myelodysplastic syndrome (MDS): Results of a randomized, double-blind, placebo (PBO)-controlled study. Retrieved from http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/117?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=117&searhid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT
Gondek, L. P., Tiu, R., O'Keefe, C. L., Sekeres, M. A., Theil, K. S., & Maciejewski, J. P. (2008). Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood, 111, 1534-1542. doi:10.1182/blood-2007-05-092304
Gore, S., Sun, Z., Prebet, T., Greenberg, P., Gabrilove, J., Erba, H., … Tallman, M. (2011). Azacitidine plus entinostat: Results from E1905, the first randomized trial adding a histone deacetylase inhibitor to a DNMT inhibitor (DNMTi) [Abstract 170]. Leukemia Research, 35(Suppl. 1), S66-S67.
Graubert, T. (2011). Molecular analysis as a diagnostic tool in myelodysplastic syndromes [Abstract 13]. Leukemia Research, 35(Suppl. 1), S5.
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., … Bennett, J. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
Greenberg, P., Tuechler, H., Schanz, J., Sole, F., Bennett, J. M., Garcia-Manero, G., … Haase, D. (2011). Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM) [Abstract 14]. Leukemia Research, 35(Suppl. 1), S6.
Greenberg, P. L. (2010). Current therapeutic approaches for patients with myelodysplastic syndromes. British Journal of Haematology, 150, 131-143. doi:10.1111/j.1365-2141.2010.08226.x
Greenberg, P. L., Sun, Z., Miller, K. B., Bennett, J. M., Tallman, M. S., Dewald, G., … Rowe, J. M. (2009). Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: Results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood, 114, 2393-2400. doi:10.1182/blood-2009-03-211797
Haase, D., Germing, U., Schanz, J., Pfeilstöcker, M., Nösslinger, T., Hildebrandt, B., … Steidl, C. (2007). New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood, 110, 4385-4395. doi:10.1182/blood-2007-03-082404
Heise, C., Carter, T., Schafer, P., & Chopra, R. (2010). Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Reviews of Anticancer Therapy, 10, 1663-1672.
Hess-Stumpp, H., Bracker, T. U., Henderson, D., & Politz, O. (2007). MS-275, a potent orally available inhibitor of histone deacetylases—The development of an anticancer agent. International Journal of Biochemistry and Cell Biology, 39(7-8), 1388-1405. doi:10.1016/j.biocel.2007.02.009
Itzykson, R., Kosmider, O., Cluzeau, T., Mas, V. M., Dreyfus, F., Beyne-Rauzy, O., … Fontenay, M. (2011). Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia, 25, 1147-1152. doi:10.1038/leu.2011.71
Jadersten, M., Saft, L., Pellagatti, A., Gohring, G., Wainscoat, J. S., Boultwood, J., … Hellstrom-Lindberg, E. (2009). Clonal heterogeneity in the 5q- syndrome: P53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica, 94, 1762-1766. doi:10.3324/haematol.2009.011528
Jadersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Gohring, G., … Mufti, G. J. (2011). TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. Journal of Clinical Oncology, 29, 1971-1979. doi:10.1200/JCO.2010.31.8576
Jang, J. H., & Lee, J. H. (2011). Pretransplant use of decitabine as a bridging therapy for myelodysplastic syndrome [Abstract 330]. Leukemia Research, 35(Suppl. 1), S132.
Jiang, Y., Dunbar, A., Gondek, L. P., Mohan, S., Rataul, M., O'Keefe, C., … Maciejewski, J. P. (2009). Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood, 113, 1315-1325. doi:10.1182/blood-2008-06-163246
Jonasova, A., Neuwirtova, R., Cermak, J., Vozobulova, V., Mocikova, K., Siskova, M., & Hochova, I. (1998). Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. British Journal of Haematology, 100, 304-309.
Kantarjian, H., Issa, J. P., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., … Saba, H. (2006). Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer, 106, 1794-1803. doi:10.1002/cncr.21792
Kantarjian, H., O'Brien, S., Ravandi, F., Cortes, J., Shan, J., Bennett, J. M., … Garcia-Manero, G. (2008). Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer, 113, 1351-1361. doi:10.1002/cncr.23697
Kantarjian, H., Oki, Y., Garcia-Manero, G., Huang, X., O'Brien, S., Cortes, J., … Issa, J. P. (2007). Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 109, 52-57. doi:10.1182/blood-2006-05-021162
Kantarjian, H. M., Giles, F. J., Greenberg, P. L., Paquette, R. L., Wang, E. S., Gabrilove, J. L., … Berger, D. P. (2010). Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood, 116, 3163-3170. doi:10.1182/blood-2010-03-274753
Klumpen, H. J., Beijnen, J. H., Gurney, H., & Schellens, J. H. (2010). Inhibitors of mTOR. Oncologist, 15, 1262-1269. doi:10.1634/theoncologist.2010-0196
Komrokji, R. S., Lancet, J. E., Yu, D., Santana, E., Yan, L., Smith, P. S., … List, A. F. (2010). Erlotinib for treatment of myelodysplastic syndromes: A phase II clinical study [Abstract 1854]. Retrieved from http://ash.confex.com/ash/2010/webprogram/Paper30141.html
Komrokji, R. S., Zhang, L., & Bennett, J. M. (2010). Myelodysplastic syndromes classification and risk stratification. Hematology/Oncology Clinics of North America, 24, 443-457. doi:10.1016/j.hoc.2010.02.004
Kurtin, S. E. (2007). Myelodysplastic syndromes: Diagnosis, treatment planning, and clinical management. Oncology (Williston Park), 21(11, Suppl. Nurse Ed.), 41-48.
Kurtin, S. E., & Demakos, E. P. (2010). An update on the treatment of myelodysplastic syndromes [Online exclusive]. Clinical Journal of Oncology Nursing, 14, E24-E39. doi:10.1188/10.CJON.E24-E39
Kurtin, S. E., Paterson, P., Wintrich, S., Iraca, T., Hassan, A. A., Murray, D., & Hogan, S. (2012). Patient and family resources for living with myelodysplastic syndromes. Clinical Journal of Oncology Nursing, 16(3, Suppl. 1), 58-64. doi:10.1188/12.CJON.S1.58-64.
Link, P. A., Baer, M. R., James, S. R., Jones, D. A., & Karpf, A. R. (2008). P53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Research, 68, 9358-9366. doi:10.1158/0008-5472.CAN-08-1860
List, A. (2011). International research activity in MDS—Novel therapeutics [Abstract 23]. Leukemia Research, 35(Suppl. 1), S9.
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., … Myelodysplastic Syndrome-003 Study Investigators. (2006). Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine, 355, 1456-1465. doi:10.1056/NEJMoa061292
Lubbert, M., Suciu, S., Baila, L., Ruter, B. H., Platzbecker, U., Giagounidis, A., … Wijermans, P. W. (2011). Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Journal of Clinical Oncology, 29, 1987-1996. doi:10.1200/JCO.2010.30.9245
Lyons, R. M., Cosgriff, T. M., Modi, S. S., Gersh, R. H., Hainsworth, J. D., Cohn, A. L., … Beach, C. L. (2009). Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. Journal of Clinical Oncology, 27, 1850-1856. doi:10.1200/JCO.2008.17.1058
Maciejewski, J. P., & Mufti, G. J. (2008). Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood, 112, 965-974. doi:10.1182/blood-2008-02-130435
Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M. G., Pascutto, C., Invernizzi, R., … Cazzola, M. (2007). Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. Journal of Clinical Oncology, 25, 3503-3510. doi:10.1200/JCO.2006.08.5696
Molldrem, J. J., Jiang, Y. Z., Stetler-Stevenson, M., Mavroudis, D., Hensel, N., & Barrett, A. J. (1998). Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. British Journal of Haematology, 102, 1314-1322.
Naqvi, K., Garcia-Manero, G., Vueso-Ramos, C. E., Pierce, S., Kadia, T., Borthakur, G., … Jabbour, E. (2010). Discrepancy in diagnosis of myelodysplastic syndromes (MDS) between referral and tertiary care centers: Experience at MD Anderson Cancer Center (MDACC) [Abstract 1870]. Retrieved from http://ash.confex.com/ash/2010/webprogram/Paper31872.html
National Comprehensive Cancer Network. (2011). NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic syndromes [v2.2011]. Retrieved from http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf
National Institute for Health and Clinical Excellence. (2012). Home page. Retrieved from http://www.nice.org/uk
Navada, S. C., & Silverman, L. R. (2011). Therapeutic modalities for patients with lower-risk myelodysplastic syndromes: Current options and future directions. Current Hematologic Malignancy Reports, 6, 5-12.
Nordic MDS Group. (2011). Home page. Retrieved from http://www.nmds.org
Oussenko, I. A., Holland, J. F., Reddy, E. P., & Ohnuma, T. (2011). Effect of ON 01910.na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation. Cancer Research, 71, 4968-4976. doi:10.1158/0008-5472.CAN-10-1603
Pan-Canadian Oncology Drug Review. (2011). Pan-Canadian Oncology Drug Review submission guidelines. Retrieved from http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr-submission-guidelines.pdf
Passweg, J. R., Giagounidis, A. A., Simcock, M., Aul, C., Dobbelstein, C., Stadler, M., … Ganser, A. (2011). Immunosuppressive therapy for patients with myelodysplastic syndrome: A prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99. Journal of Clinical Oncology, 29, 303-309. doi:10.1200/JCO.2010.31.2686
Pharmaceuticals and Medical Devices Agency. (2012). 2012 PMDA risk communications. Retrieved from http://www.pmda.go.jp/english/index.html
Prince, H. M., Bishton, M. J., & Johnstone, R. W. (2009). Panobinostat (LBH589): A potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncology (London, England), 5, 601-612. doi:10.2217/fon.09.36
Raza, A., Galili, N., Smith, S., Godwin, J., Lancet, J., Melchert, M., … List, A. (2009). Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood, 113, 6533-6540. doi:10.1182/blood-2009-01-176032
Raza, A., Greenberg, P. L., Olnes, M. J., Silverman, L. R., Wilhelm, F. (2011). Final phase I/II results of rigosertib (ON01910. Na) hematological effects in patients with myelodysplastic syndrome and correlation with overall survival. Retrieved from http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/3822?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=3822&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT
Rizzo, J. D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M. O., Spivak, J. L., … Somerfield, M. R. (2010). American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Journal of Clinical Oncology, 28, 4996-5010. doi:10.1200/JCO.2010.29.2201
Saunthararajah, Y., Nakamura, R., Nam, J., Robyn, J., Loberiza, F., Maciejewski, J. P., … Barrett, A. J. (2002). HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood, 100, 1570-1574.
Schanz, J., Tüchler, H., Sole, F., Mallo, M., Hildebrandt, B., Slovak, M., … Haase, D. (2010). Proposal of a new, comprehensive cytogenetic scoring system for primary MDS [Abstract 0535]. Haematologica, 95(S2), 219.
Shah, J., Kurtin, S. E., Arnold, L., Lindroos-Kolqvist, P., & Tinsley, S. (2012). Management of tranfusion-related iron overload in patients with myelodysplastic syndromes. Clinical Journal of Oncology Nursing, 16(3, Suppl. 1), 37-46. doi:10.1188/12.CJON.S1.37-46.
Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., … Holland, J. F. (2002). Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. Journal of Clinical Oncology, 20, 2429-2440.
Silverman, L. R., Fenaux, P., Mufti, G. J., Santini, V., Hellstrom-Lindberg, E., Gattermann, N., … Seymour, J. F. (2011). Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer, 117, 2697-2702. doi:10.1002/cncr.25774
Sloand, E. M., & Barrett, A. (2010). Immunosuppression for myelodysplastic syndrome: How bench to bedside to bench research led to success. Hematology/Oncology Clinics of North America, 24, 331-341.
Sloand, E. M., Olnes, M. J., Shenoy, A., Weinstein, B., Boss, C., Loeliger, K., … Young, N. S. (2010). Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. Journal of Clinical Oncology, 28, 5166-5173. doi:10.1200/JCO.2010.29.7010
Sloand, E. M., Wu, C. O., Greenberg, P., Young, N., & Barrett, J. (2008). Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. Journal of Clinical Oncology, 26, 2505-2511. doi:10.1200/JCO.2007.11.9214
Steensma, D. P., Baer, M. R., Slack, J. L., Buckstein, R., Godley, L. A., Garcia-Manero, G., … Kantarjian, H. (2009). Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) trial. Journal of Clinical Oncology, 27, 3842-3848. doi:10.1200/JCO.2008.19.6550
SuperGen, Inc. (2010). Dacogen® (decitabine) [Prescribing information]. Retrieved from http://us.eisai.com/pdf_files/Dacogen_PI.pdf
Thomas, M. L., Crisp, N., & Campbell, K. (2012). The importance of quality of life for patients living with myelodysplastic syndromes. Clinical Journal of Oncology Nursing, 16(3, Suppl. 1), 47-57. doi:10.1188/12.CJON.S1.47-57.
Tiu, R. V., Visconte, V., Traina, F., Schwandt, A., & Maciejewski, J. P. (2011). Updates in cytogenetics and molecular markers in MDS. Current Hematologic Malignancy Reports, 6, 126-135. doi:10.1007/s11899-011-0081-2
U. S. Food and Drug Administration. (2012). Home page. Retrieved from http://www.fda.gov
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., … Bloomfield, C. D. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood, 114, 937-951. doi:10.1182/blood-2009-03-209262
Westers, T., Ireland, R., Kern, W., Alhan, C., Balleisen, J., Bene, M. C., … van de Loosdrecht, A. A. (2011). Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group [Abstract 137]. Leukemia Research, 35(Suppl. 1), S53.
Wroblewski, S., Shi, W., Mudd, P., & Aivado, M. (2010). Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukemia after MDS: A phase I/II study [Abstract TPS184]. Journal of Clinical Oncology, 28(15S), 27s.
Yoo, C. B., & Jones, P. A. (2006). Epigenetic therapy of cancer: Past, present, and future. Nature Reviews Drug Discovery, 5, 37-50.